By LARRY SWEDROE
My May 7, 2021, Evidence-Based Investor article, Spac or Spam?, warned investors about investing in special-purpose acquisition companies (SPACs), presenting evidence demonstrating that SPACs were highly likely to be losing propositions to their shareholders due to the unfavourable incentives built into the SPAC structure that result in the SPAC sponsors doing well even if SPAC shareholders experience substantial losses. The article made the case that it was difficult to believe this was a sustainable arrangement, as at some point SPAC shareholders would become more skeptical of the mergers that sponsors pitch.
In other words, SPACs were a bubble that likely would burst. Forewarned was forearmed.
Thanks to JP Morgan, we now have more evidence on just how poor an investment SPACs have been for their shareholders. The table below provides a return analysis for investors in SPAC companies brought public or liquidated from January 1, 2019, to March 5, 2021, with the median cumulative returns through August 17, 2021:
JP Morgan noted: “These sub-par outcomes are not just the case with 2019-March 2021 SPACS. We ran the same analysis for the 85 SPAC mergers since March 2021, and the same patterns hold: enormous returns for SPAC sponsors, low positive absolute returns for SPAC Arbitrage investors and negative returns for everybody else.”
They added: “Institutional ‘PIPE’ financing has dried up, forcing sponsors to allocate more of their economics to securing institutional commitments that are guaranteed to fund at closing; and increased risk that SPACs do not find a merger partner before their two-year lifespan, in which case the SPAC would be unwound, SPAC investors would receive their capital back and sponsors would lose all of their upfront investment.”
And finally, they added this caution: “SPACs may be an exaggerated preview of what lies in store for other overpriced assets unsupported by earnings growth.” Again, forewarned is forearmed.
One of the benefits of working with a good wealth adviser is that they prevent you from investing in products that were meant to be sold, never bought.
© The Evidence-Based Investor MMXXIV. All rights reserved. Unauthorised use and/ or duplication of this material without express and written permission is strictly prohibited.